Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: Monash Alfred Psychiatry Research Centre (MAPrc)
Location: Level 4, 607 St Kilda Rd Melbourne 3004
Lead Doctor: Professor Jayashri Kulkarni
IRB Committee: This study has been reviewed and approved by the Alfred Hospital Human Research Ethics Committee

Background

 

Schizophrenia is a complex mental illness and can be significantly debilitating to those who are diagnosed. The current treatments available for schizophrenia have shown to have inconsistent effects.

This research study is investigating the effectiveness of a new potential hormone treatment that may help improve symptoms of schizophrenia. From past research studies, this new potential treatment has shown to be safe and well-tolerated. 

Interested participants must be adults aged 18 to 65 years old who are diagnosed with schizophrenia or related disorder. Participants must be stable on their current medication treatment for at least 4 weeks This is a 12-week study, which requires participants to attend at least 4 out of 12 of the study visits at the research site.

Why Participate? 

 

• You may experience improvements to your schizophrenia symptoms.
• You will receive your results from the study at the end of your participation. 
• You may help others diagnosed with schizophrenia in the future.
• You will meet with a qualified psychiatrist. 
• You will be helping to advance research on schizophrenia.

Your Rights

 

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

 

• Adults aged 18 to 65 years old who are diagnosed with schizophrenia or related disorder.
• Whose condition is currently stable due to current treatment therapy.
• Able to attend 4 study visits at the research site over approximately 12 weeks.
• Not currently using hormone treatment, including the use of the pill (for female participants)

Please note:

Due to the current situation with COVID-19 pandemic, the study team would like to point out the following:

• The research site does not treat COVID-19 patients and/or suspected COVID-19 patients.
• The research site’s waiting area is spacious enough that participants will not be within close proximity to each other.
• Hand sanitisers are available at the research site.
• The research staff adheres to strict hygienic practices as well as other safety measures to prevent the spread of COVID-19. 
• Any staff suspected to have COVID-19, or has come into contact with someone who has COVID-19, will automatically undergo a voluntary quarantine for 14 days.
• Interested participants will not be left waiting for a long period of time and will be quickly attended to. 
• The study team encourages the use of personal vehicles, taxi or rideshare services rather than public transit.
• The research site/institution is taking all precautionary measures to ensure the safety of the study participants.